TrialAnnals of the rheumatic diseases2020

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).

Maxime Dougados et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.